Animal models of Parkinson's disease

Parkinson's Disease: Diagnosis, Motor Symptoms and Non-Motor Features

Volumn , Issue , 2013, Pages 115-135

  Le, Weidong ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893105563     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.13.115     Document Type: Chapter

References (41)

1. Bezard E, Przedborski S. A tale on animal models of Parkinson's disease. Mov. Disord. 26(6), 993-1002 (2011).
2. Blandini F, Armentero MT. Animal models of Parkinson's disease. FEBS J. 279, 1156-1166 (2012).
3. Chesselet M, Richter F. Modeling of Parkinson's disease in mice. Lancet Neurol. 10, 1108-1118 (2011).
4. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron 66(5), 646-661 (2010).
5. Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol. 6, 193-222 (201 1).
6. Flinn L, Bretaud S, Lo C, Ingham PW, Bandmann O. Zebrafish as a new animal model for movement disorders. J. Neurochem. 106(5), 1991-1997 (2008).
7. Tieu K. A Guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb. Perspect. Med. 1, a009316 (2011).
8. Potashkin JA, Blume SR, Runkle NK. Limitations of animal models of Parkinson's disease. Parkinsons Dis. 2011, 658083 (2010).
9. Tanner CM, Kamel F, Ross GW et al. Rotenone, paraquat and Parkinson's disease. Environ. Health Perspect. Nat. 119(6), 866-872 (2011).
10. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587), 979-980 (1983).
11. Chiueh CC, Markey SP, Burns RS et al. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol. Bull. 20(3), 548-553 (1984).
12. Betarbet R, Sherer TB, MacKenzie G et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3(12), 1301-1306 (2000).
13. Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol. 44(3 Suppl. 1), S115-S120 (1998).
14. Castaño A, Herrera AJ, Cano J, Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 70(4), 1584-1592 (1998).
15. Morrison B, Marcondes M, Nomura D. IL-13Ra1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide. J. Immunol. 189(12), 5498-5502 (2012).
16. Le W, Rowe D, Xie WJ, He Y, Appel SH. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 21, 8447-8455 (2001).
17. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56(1), 149-162 (2004).
18. Xie W, Li X, Li C, Zhu W, Jankovic J, Le W. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J. Neurochem. 115(1), 188-199 (2010).
19. Vernon AC, Johansson SM, Modo MM. Non-invasive evaluation of nigro-striatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. BMC Neurosci. 11, 1 (2010).
20. Klein C, Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb. Perspect. Med. 2(1), a008888 (2012).
21. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209(5), 975-986 (2012).
22. Freundt EC, Maynard N, Clancy EK et al. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann. Neurol. 72(4), 517-524 (2012).
23. Lin X, Parisiadou L, Gu XL et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathologyinduced by Parkinson's-disease-related mutant α-synuclein. Neuron 64(6), 807-827 (2009).
24. Tong Y, Yamaguchi H, Giaime E et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice. Proc. Natl Acad. Sci. USA 107(21), 9879-9884 (2010).
25. Yue Z, Lachenmayer ML. Genetic LRRK2 models of Parkinson's disease: dissecting the pathogenic pathway and exploring clinical applications. Mov. Disord. 26(8), 1386-1397 (201 1).
26. Kim RH, Smith PD, Aleyasin H. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl Acad. Sci. USA 102(14), 5215-5220 (2005).
27. Jankovic J, Chen S, Le W. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog. Neurobiol. 77, 128-138 (2005).
28. Le W, Chen S, Jankovic J. Etiopathogenesis of Parkinson's disease: a new beginning? Neuroscientist 15, 28-35 (2009).
29. Li J, Dani JA, Le W. The role of transcription factor Pitx3 in dopamine neuron development and Parkinson's disease. Curr. Top. Med. Chem. 9(10), 855-859 (2009).
30. Taylor TN, Caudle WM, Shepherd KR et al. Non-motor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 29(25), 8103-8113 (2009).
31. Brooks SP, Dunnett SB. Tests to assess motor phenotype in mice: a user's guide. Nat. Rev. Neurosci. 10(7), 519-529 (2009).
32. Taylor TN, Greene JG, Miller GW. Behavioral phenotyping of mouse models of Parkinson's disease. Behav. Brain Res. 211(1), 1-10 (2010).
33. Chaudhuri KR, Healy DG, Schapira AH. National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5(3), 235-245 (2006).
34. Reetz K, Gaser C, Klein C et al. Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson's disease. Mov. Disord. 24(1), 99-103 (2009).
35. Varrone A, Halldin C. New developments of dopaminergic imaging in Parkinson's disease. Q. J. Nucl. Med. Mol. Imaging 56(1), 68-82 (2012).
36. Saiki H, Hayashi T, Takahashi R, Takahashi J. Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease. J. Neurosci. Methods 15, 190(2), 198-204 (2010).
37. Emborg ME. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J. Neurosci. Methods 139(2), 121-143 (2004).
38. Eschbach J, Dupuis L. Cytoplasmic dynein in neurodegeneration. Pharmacol. Ther. 130(3), 348-363 (2011).
39. Chu Y, Morfini GA, Langhamer LB et al. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 135, 2058-2073 (2012).
40. Zhang Z, Li X, Xie W et al. Anti-Parkinsonian effects of nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol. Disord. Drug Targets 1 1(6), 768-773 (2012).
41. Le W, Jakkoju A, Jankovic J. Animal models of Parkinson's disease to test therapeutics. Neurotherapeutics (2013) (In press).